Artios Pharma Announces $84 Million (£65 Million) Series B FinancingFinancing Round Led by New Investors Andera Partners and LSP CAMBRIDGE, England, August 10, 2018-- Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, today announced the completion of a $84 million (£65 million) Series B financing following high interest from investors. The financing, which was significantly oversubscribed, was led by Andera Partners (formerly EdRIP) and LSP (Life Sciences Partners), with participation by additional new investors Pfizer Ventures and Novartis Venture Fund (NVF).